Table 1.
Baseline demographics
| Characteristics | Young (18–39 years) (n = 243) |
Middle age (40–59 years) (n = 494) |
Elderly (60–74 years) (n = 300) |
Old (≥75 years) (n = 52) |
|---|---|---|---|---|
| Median age (range), years | 32 (18–39) | 50 (40–59) | 66 (60–74) | 78 (75–91) |
| Male/female (%) | 159/84 (34.6%) | 286/208 (42.1%) | 172/128 (42.7%) | 25/27 (51.9%) |
| Time since initial diagnosis of CML (months); median (range) | 0.86 (0.07, 5.86) | 0.92 (0.07, 6.61) | 0.92 (0.03, 60.99) | 0.86 (0.07, 6.02) |
| Sokal score, n (%) | ||||
| High risk | 31 (12.8) | 84 (17.0) | 71 (23.7) | 11 (21.2) |
| Intermediate risk | 52 (21.4) | 161 (32.6) | 159 (53.0) | 36 (69.2) |
| Low risk | 135 (55.6) | 203 (41.1) | 39 (13.0) | – |
| Missing | 25 (10.3) | 46 (9.3) | 31 (10.3) | 5 (9.6) |
| EUTOS score, n (%) | ||||
| High risk | 31 (12.8) | 39 (7.9) | 22 (7.3) | 2 (3.8) |
| Low risk | 190 (78.2) | 412 (83.4) | 252 (84.0) | 46 (88.5) |
| Missing | 22 (9.1) | 43 (8.7) | 26 (8.7) | 4 (7.7) |
| Laboratory parameters | ||||
| Peripheral blasts %, mean ± SD (n) | 2.05 ± 3.03 (230) | 1.60 ± 2.33 (475) | 1.49 ± 2.25 (283) | 0.98 ± 1.04 (48) |
| Peripheral eosinophils %, mean ± SD (n) | 2.88 ± 3.37 (234) | 2.73 ± 2.64 (479) | 2.85 ± 3.14 (289) | 2.47 ± 2.37 (49) |
| Peripheral basophils %, mean ± SD (n) | 4.02 ± 3.75 (234) | 4.07 ± 3.83 (478) | 4.08 ± 3.95 (292) | 3.89 ± 3.72 (50) |
| Platelets (109/L), mean ± SD (n) | 446.47 ± 312.07 (240) | 464.08 ± 352.63 (487) | 463.28 ± 308.61 (297) | 423.69 ± 233.39 (51) |
| Spleen size, cm | 5.01 ± 6.19 (226) | 3.22 ± 4.90 (461) | 2.46 ± 4.13 (276) | 1.53 ± 3.06 (49) |
| Previous CML therapy, n (%) | ||||
| Imatinib ≤1 month | 17 (7) | 32 (6.5) | 16 (5.3) | 2 (3.8) |
| Imatinib >1–2 months | 13 (5.3) | 33 (6.7) | 24 (8.0) | 1 (1.9) |
| Imatinib >2–3 months | 16 (6.6) | 20 (4) | 10 (3.3) | 4 (7.7) |
CML chronic myeloid leukemia, EUTOS European Treatment Outcome Study